Research Article

Predictors of Effectiveness of Glucagon-Like Peptide-1 Receptor Agonist Therapy in Patients with Type 2 Diabetes and Obesity

Table 8

Glucose-dependent insulinotropic polypeptide level after 24 weeks of treatment in different groups depending on HbA1c reduction.

HbA1c reductionAt baselineAfter 24 months value

Responders396.9 (358.7; 488.8)429.0 (396.7; 469.3)0.375
Nonresponders376.0 (250.2; 436.7)430.0 (338.1; 503.1)0.039